Pacific Shuanglin Bio-pharmacy Co., Ltd. (SHE:000403)
China
· Delayed Price · Currency is CNY 12.17
-0.11 (-0.90%)
Apr 29, 2026, 3:04 PM CST
SHE:000403 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Operating Revenue | 2,601 | 2,633 | 2,654 | 2,325 | 2,396 | 1,966 | Upgrade
|
| Other Revenue | - | - | 1.05 | 3.27 | 9.59 | 5.27 | Upgrade
|
| Revenue | 2,601 | 2,633 | 2,655 | 2,329 | 2,405 | 1,972 | Upgrade
|
| Revenue Growth (YoY) | 0.28% | -0.83% | 14.00% | -3.18% | 21.98% | 87.80% | Upgrade
|
| Cost of Revenue | 1,568 | 1,539 | 1,352 | 1,130 | 1,151 | 1,064 | Upgrade
|
| Gross Profit | 1,033 | 1,093 | 1,303 | 1,199 | 1,254 | 907.93 | Upgrade
|
| Selling, General & Admin | 444.44 | 438.17 | 437.26 | 465.81 | 565.05 | 419 | Upgrade
|
| Research & Development | 56.13 | 55.92 | 55.18 | 79.69 | 75.36 | 35.63 | Upgrade
|
| Other Operating Expenses | 15.76 | 12.81 | 22.07 | 21.69 | 16.8 | 15.28 | Upgrade
|
| Operating Expenses | 516.33 | 506.9 | 509.9 | 565.15 | 666.86 | 477.73 | Upgrade
|
| Operating Income | 516.47 | 586.54 | 793.13 | 633.7 | 587.01 | 430.2 | Upgrade
|
| Interest Expense | - | - | -10.67 | -9.63 | -12.03 | -10.78 | Upgrade
|
| Interest & Investment Income | 6.03 | 8.95 | 78.01 | 75.08 | 68.22 | 62.3 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | 0.13 | -0.12 | 2.4 | -0.21 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.83 | -0.19 | 0.03 | 0.64 | -2.23 | -3.44 | Upgrade
|
| EBT Excluding Unusual Items | 519.67 | 595.3 | 860.61 | 699.67 | 643.37 | 478.06 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | - | -103.18 | Upgrade
|
| Gain (Loss) on Sale of Investments | 5.68 | 4.3 | 6.38 | -18.97 | 4.93 | 74.21 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.72 | 0.76 | -0.12 | -0.54 | 0.44 | 0.27 | Upgrade
|
| Asset Writedown | -100.05 | -100.05 | -3.46 | -1.29 | -3.59 | -0.49 | Upgrade
|
| Legal Settlements | - | - | - | - | - | -2.14 | Upgrade
|
| Other Unusual Items | - | - | -10.87 | 9.25 | 15.24 | 11.28 | Upgrade
|
| Pretax Income | 426.02 | 500.3 | 852.78 | 688.11 | 660.39 | 458.01 | Upgrade
|
| Income Tax Expense | 72.69 | 80.77 | 107.74 | 76.64 | 72.7 | 66.47 | Upgrade
|
| Earnings From Continuing Operations | 353.33 | 419.54 | 745.04 | 611.47 | 587.69 | 391.54 | Upgrade
|
| Minority Interest in Earnings | -0.18 | -0.27 | 0.28 | 0.64 | -0.56 | -0.48 | Upgrade
|
| Net Income | 353.15 | 419.27 | 745.32 | 612.11 | 587.13 | 391.06 | Upgrade
|
| Net Income to Common | 353.15 | 419.27 | 745.32 | 612.11 | 587.13 | 391.06 | Upgrade
|
| Net Income Growth | -50.43% | -43.75% | 21.76% | 4.25% | 50.14% | 110.29% | Upgrade
|
| Shares Outstanding (Basic) | 993 | 953 | 950 | 947 | 950 | 917 | Upgrade
|
| Shares Outstanding (Diluted) | 993 | 953 | 950 | 947 | 950 | 919 | Upgrade
|
| Shares Change (YoY) | 2.33% | 0.31% | 0.28% | -0.33% | 3.38% | 44.25% | Upgrade
|
| EPS (Basic) | 0.36 | 0.44 | 0.78 | 0.65 | 0.62 | 0.43 | Upgrade
|
| EPS (Diluted) | 0.36 | 0.44 | 0.78 | 0.65 | 0.62 | 0.43 | Upgrade
|
| EPS Growth | -51.56% | -43.92% | 21.42% | 4.60% | 45.23% | 45.78% | Upgrade
|
| Free Cash Flow | -544.84 | -549.39 | -198.92 | 301.74 | 145.58 | 82.06 | Upgrade
|
| Free Cash Flow Per Share | -0.55 | -0.58 | -0.21 | 0.32 | 0.15 | 0.09 | Upgrade
|
| Dividend Per Share | - | - | 0.385 | 0.154 | 0.062 | 0.043 | Upgrade
|
| Dividend Growth | - | - | 150.06% | 149.27% | 43.16% | - | Upgrade
|
| Gross Margin | 39.71% | 41.53% | 49.08% | 51.48% | 52.13% | 46.05% | Upgrade
|
| Operating Margin | 19.86% | 22.28% | 29.88% | 27.21% | 24.41% | 21.82% | Upgrade
|
| Profit Margin | 13.58% | 15.93% | 28.08% | 26.28% | 24.41% | 19.83% | Upgrade
|
| Free Cash Flow Margin | -20.95% | -20.87% | -7.49% | 12.96% | 6.05% | 4.16% | Upgrade
|
| EBITDA | 657.53 | 723.55 | 913.93 | 770.71 | 704.63 | 538.01 | Upgrade
|
| EBITDA Margin | 25.28% | 27.48% | 34.43% | 33.10% | 29.30% | 27.29% | Upgrade
|
| D&A For EBITDA | 141.06 | 137.01 | 120.8 | 137.02 | 117.62 | 107.82 | Upgrade
|
| EBIT | 516.47 | 586.54 | 793.13 | 633.7 | 587.01 | 430.2 | Upgrade
|
| EBIT Margin | 19.86% | 22.28% | 29.88% | 27.21% | 24.41% | 21.82% | Upgrade
|
| Effective Tax Rate | 17.06% | 16.14% | 12.63% | 11.14% | 11.01% | 14.51% | Upgrade
|
| Revenue as Reported | - | - | 2,655 | 2,329 | 2,405 | 1,972 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.